Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HySBst in Stage II-III NSCLC
NCT02252796Phase 1Terminated
- Sponsor
- West Virginia University
- Start
- Jul 2014
- Primary completion
- Sep 2017
- Countries
- 1
01
Overview
Phase 1, open-label trial in non-small cell lung cancer (NSCLC) (2 arms), sponsored by West Virginia University. Primary endpoint: Maximum Tolerated Dose of HySBst at 2 years. Started Jul 2014; status: terminated.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02252796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02252796.